There was a notable rise in CXCL9 expression in patients with joint involvement, rash involvement, blood involvement, kidney involvement, and ILD, compared to pSS-non-EGM patients, except for those with peripheral nervous system involvement. Here, CXCL9 is linked to peeling skin syndrome.